Literature DB >> 11317203

Polymorphisms of the renin-angiotensin system in patients with multifocal renal arterial fibromuscular dysplasia.

A Bofinger1, C Hawley, P Fisher, N Daunt, M Stowasser, R Gordon.   

Abstract

Fibromuscular dysplasia (FMD) is an important cause of renal artery stenosis, particularly in young females. Polymorphisms of the renin-angiotensin (RA) system have been implicated in the pathogenesis of hypertension and atherosclerotic vascular disease, and may play a role in the development of FMD. Examination of polymorphisms by PCR for angiotensin-converting enzyme (ACE) I/D, angiotensin II type 1 receptor (AT1R) A1166C and angiotensinogen (AGT) M235T and T174M was undertaken in 43 patients with typical multifocal renal arterial FMD (MF-FMD) and in 89 controls. The age of MF-FMD patients at the time of diagnosis of hypertension did not differ (38.6 + 11.1 years vs 35.5 +/- 10.3 years, P = 0.12) from controls and the proportion (95% vs 86%, P = 0.14) of females was similar. Allele frequencies did not differ significantly between groups, except that MF-FMD patients had a significantly higher frequency of the ACE I allele than control subjects (0.62 vs 0.47, P = 0.026). Since the ACE I allele is associated with lower circulating ACE levels and possibly lower tissue levels of angiotensin II (Ang II), and since Ang II modulates vascular smooth muscle cell growth and synthetic activity, the I allele might predispose to defective remodelling of the arterial media, and thus to the development of MF-FMD. This contrasts with atherosclerotic renal artery stenosis, coronary stent restenosis and carotid intimal thickening, which are diseases affecting the arterial intima, and which are associated with increased frequency of the D allele.

Entities:  

Mesh:

Year:  2001        PMID: 11317203     DOI: 10.1038/sj.jhh.1001144

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

1.  Renal FMD may not confer a familial hypertensive risk nor is it caused by ACTA2 mutations.

Authors:  Stephen D Marks; Ambrose M Gullett; Eileen Brennan; Kjell Tullus; Graciana Jaureguiberry; Enriko Klootwijk; Horia C Stanescu; Robert Kleta; Adrian S Woolf
Journal:  Pediatr Nephrol       Date:  2011-05-08       Impact factor: 3.714

2.  Fibromuscular dysplasia of the lower extremities.

Authors:  Jin Okazaki; Atsushi Guntani; Kenichi Homma; Ryoichi Kyuragi; Eisuke Kawakubo; Yoshihiko Maehara
Journal:  Ann Vasc Dis       Date:  2011-06-02

Review 3.  Fibromuscular dysplasia: an uncommon cause of secondary hypertension.

Authors:  L Michael Prisant; Harold M Szerlip; Laura L Mulloy
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

Review 4.  Optimal management of renal artery fibromuscular dysplasia.

Authors:  Anders Gottsäter; Bengt Lindblad
Journal:  Ther Clin Risk Manag       Date:  2014-07-28       Impact factor: 2.423

Review 5.  Renal Fibromuscular Dysplasia: A Not So Common Entity of Secondary Hypertension.

Authors:  Elias A Sanidas; Maria Seferou; Dimitris P Papadopoulos; Anastasios Makris; Nora A Viniou; Vasiliki Chantziara; Vasiliki Cennimata; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-08-19       Impact factor: 3.738

Review 6.  Fibromuscular dysplasia.

Authors:  Pierre-François Plouin; Jérôme Perdu; Agnès La Batide-Alanore; Pierre Boutouyrie; Anne-Paule Gimenez-Roqueplo; Xavier Jeunemaitre
Journal:  Orphanet J Rare Dis       Date:  2007-06-07       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.